Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lenvima Stars As Eisai Ups Profit Outlook After Solid Quarter

Executive Summary

Growing use in liver cancer drives global sales of Lenvima along with the overall performance of Eisai.

You may also be interested in...



Biogen Is Putting Its Money Where Its Mouth Is – Behind The Launch Of Aducanumab

US FDA approval of the Alzheimer's drug may be uncertain, but Biogen will be investing substantially behind a commercial buildout this year.

First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon

Eisai and Merck won the first US FDA approval in 10 years for a first-line hepatocellular carcinoma treatment with Lenvima, but challengers are on the horizon. The companies' recent partnership and plans for combination therapy with Keytruda may defend the drug's standing in liver cancer.

Podcast: Scrip’s Asia Team Dissects Pharma’s Response To Coronavirus

Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141593

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel